Clinical Trial

Precision Brain Mapping to Predict and Track Response to Exposure and Response Prevention Therapy in Youth With Obsessive-Compulsive Disorder

Withdrawn
View on ClinicalTrials.gov →
Why the trial stopped
Study withdrawn before participant enrollment because the research team does not plan to initiate the study at this time. The protocol may be reconsidered in the future.
Summary
The goal of this clinical trial is to learn whether brain scan results can help predict and track changes in obsessive-compulsive disorder, or OCD, symptoms in children and teens ages 10 to 17 who receive Exposure and Response Prevention therapy, also called ERP. ERP is a type of therapy in which participants practice facing OCD-related fears while resisting rituals or compulsions. The main question this study aims to answer is: Can each participant's pattern of brain connections, measured with functional MRI brain scans, help predict and track weekly changes in OCD symptoms during and after a 14-week course of ERP, including during planned monthly booster sessions and additional booster sessions offered if symptoms worsen? All participants will receive ERP. There is no placebo and no comparison group. Participants will: * Complete screening, consent or assent, interviews, questionnaires, and MRI safety checks * Receive 14 weekly ERP sessions * Complete OCD symptom assessments and functional MRI brain scans before, during, and after ERP * Receive planned monthly ERP booster sessions after the 14 weekly sessions * Receive additional brief ERP booster sessions if OCD symptoms worsen during follow-up * Take part for up to about 62 weeks
Protocol Amendment History 5 changes
critical Withdrawn before enrolling 2026-08-06
critical Trial withdrawn: Study withdrawn before participant enrollment because the research team does not plan to initiate the study at this time... 2026-08-06
notable Enrollment reduced: 30 -> 0 participants 2026-08-06
notable Primary completion pushed: 2030-09 -> 2030-11-01 2026-08-06
minor Completion pushed: 2031-08 -> 2031-11-01 2026-08-06
Trial Details
NCT Number NCT07570108
Lead Sponsor Weill Medical College of Cornell University
Conditions Obsessive-Compulsive Disorder
Start Date 2026-11-01
Primary Completion 2030-11-01 (estimated)
Study Completion 2031-11-01 (estimated)
Updated on ClinicalTrials.gov 2026-08-05